Author

Taku Kobayashi 1

1 Kitasato University Kitasato Institute Hospital, Tokyo, Japan

EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED DEEP REMISSION IN ULCERATIVE COLITIS

Shintaro Sagami, Taku Kobayashi, Ryo Karashima, Aya Hojo, Hiromu Morikubo, Yusuke Miyatani, Tomohiro Fukuda, Kunio Asonoma, Masaru Nakano, Toshifumi Hibi

EFFICACY AND SAFETY OF A NEW VEDOLIZUMAB SUBCUTANEOUS FORMULATION FOR ULCERATIVE COLITIS: RESULTS OF THE VISIBLE 1 PHASE 3 TRIAL

William Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, ;Geert R. D'Haens, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Krisztina Kisfalvi, Severine Vermeire

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens, Taku Kobayashi, Nathan Morris, Trevor Lissoos, Amy Hoover, Xingyuan Li, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro, Rish Pai, Taku Kobayashi, Vipul Jairath, Florian Rieder, Isabel Redondo, Trevor Lissoos, Nathan Morris, Mingyang Shan, Laurent Peyrin-Biroulet

EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN’S DISEASE

Ryuichi Iwakiri, Taku Kobayashi, Nikhil Patidar, Eri Udagawa, Sai Phanindra Venkatapurapu, Marcelo Behar, Ryoko Takayama, Paul D'Alessandro, Jovelle Fernandez

INDIGO NATURALIS IS EFFECTIVE FOR INDUCING CLINICAL REMISSION AND MUCOSAL HEALING IN PATIENTS WITH ULCERATIVE COLITIS (INDIGO STUDY)

Makoto Naganuma, Shinya Sugimoto, Keiichi Mitsuyama, Taku Kobayashi, Naoki Yoshimura, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Kenji Watanabe, Takayuki Abe, Yasuo Suzuki, Toshifumi Hibi, Takanori Kanai

SAFETY AND EFFICACY OF HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Taku Kobayashi, Hiroki Tanaka, Takuya Yoshino, Akihiro Yamada, N. Kamata, Toshifumi Hibi

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Severine Vermeire, Chinyu Su, Nervin Lawendy, Taku Kobayashi, William Sandborn, David T. Rubin, Irene Modesto, Sean Gardiner, nicole kulisek, Haiying Zhang, Wenjin Wang, Julian Panés

USEFULNESS OF COMBINATION THERAPY WITH ADALIMUMAB AND IMMUNOMODULATORS IN PATIENTS WITH CROHN’S DISEASE: A LARGE, MULTI-CENTRE COHORT STUDY

Hiroki Tanaka, N. Kamata, Akihiro Yamada, Toshimitsu Fujii, Katsuya Endo, Takuya Yoshino, Shigeki Bamba, Takeshi Sugaya, Takaaki Kawaguchi, Manabu Ishii, Shinichiro Shinzaki, Yosuke Toya, Yuka Yanai, Yoko Yokoyama, Junji Umeno, Toshihiko Okada, Taku Kobayashi, Masanori Nojima, Toshifumi Hibi

Usefulness of leucine-rich alpha-2-glycoprotein (LRG) to monitor the efficacy of adalimumab treatment in patients with ulcerative colitis (PLANET study)

Hideki Iijima, Shinta Mizuno, Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hiroki Tanaka, Fuminao Takeshima, Shingo Kato, Takehiro Torisu, Michio Nakagawa, Shiro Nakamura, Naoki Yoshimura, Taku Kobayashi, Akiko Shiotani, Fumihito Hirai, Sakiko Hiraoka, Minoru Matsuura, Yasuo Suzuki, Mamoru Watanabe, Tetsuo Takehara, Takayuk

Item 1 - 10 / 11
1
2